Newsletter

Blockbuster Biologics Review

2018

Blockbuster Biologics Review, produced by our Intellectual Property lawyers, covers developments in inter partes review (IPR) and patent litigation challenges to blockbuster biologic drugs.

These quarterly reports provide updates on the following topics:

  • The current status of IPR challenges to blockbuster biologics
  • The institution and invalidation rates for IPRs challenging blockbuster biologics
  • The current status of patent litigations implicating blockbuster biologics

We will continue to monitor developments and provide updates regularly.

Issue 2 (July 2018) >>

Issue 1 (April 2018) >>